文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

庆大霉素对比头孢曲松治疗淋病(G-TOG试验):一项随机试验的研究方案

Gentamicin versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a randomised trial.
PubMed 文献 · Trials · 2016-11-24

淋病治疗中头孢曲松耐药日益增加,本试验为盲法、两臂、多中心、非劣效性随机试验,计划纳入720例16-70岁生殖器、咽部和/或直肠淋病患者,比较单次肌内注射庆大霉素与头孢曲松(所有参与者均口服阿奇霉素1 g作为标准治疗),主要结局为治疗后2周所有感染部位核酸扩增检测阴性。

要点

  • 头孢曲松耐药增加,需评估庆大霉素是否非劣效于头孢曲松。
  • 计划样本量720例,非劣效界值5%。
  • 主要结局为治疗后2周所有感染部位淋病奈瑟菌核酸扩增检测转阴。

核心结论

  • 该随机试验结果将显示庆大霉素治疗淋病是否不劣于头孢曲松,为头孢菌素不再有效或存在禁忌时的临床实践和政策提供依据。

研究设计与样本

  • 盲法、两臂、多中心、非劣效性随机试验,计划样本量720例。
  • 纳入16-70岁确诊生殖器、咽部和/或直肠淋病患者。
  • 排除标准包括已知合并其他性传播感染(衣原体除外)、细菌性阴道病和/或阴道毛滴虫感染、对庆大霉素/头孢曲松/阿奇霉素/利多卡因禁忌或过敏、妊娠或哺乳、复杂性淋病感染、体重低于40 kg、前28天内使用过头孢曲松/庆大霉素/阿奇霉素。
  • 随机接受单次肌内注射庆大霉素或头孢曲松,所有参与者均接受口服阿奇霉素1 g作为标准治疗。

主要发现

  • 主要结局为治疗后2周所有感染部位核酸扩增检测阴性(淋病奈瑟菌清除)。
  • 次要结局包括症状临床缓解、不良事件频率、治疗耐受性、临床疗效与淋病奈瑟菌最低抑菌浓度的关系以及成本效益。

关键数值与推荐

  • 非劣效界值为5%。
  • 所有参与者均接受口服阿奇霉素1 g作为标准治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gonorrhoea is a common sexually transmitted infection which causes genital pain and discomfort; in women it can also lead to pelvic inflammatory disease and infertility, and in men to epididymo-orchitis. Current treatment is with ceftriaxone, but there is increasing evidence of antimicrobial resistance which is reducing its effectiveness against gonorrhoea. A small, but increasing, number of patients have already been found to have highly resistant strains of gonorrhoea which has been associated with clinical failure. This trial aims to determine whether gentamicin is not clinically worse than ceftriaxone in the treatment of gonorrhoea. METHODS/DESIGN: This is a blinded, two-arm, multicentre, noninferiority randomised trial. Patients are eligible if they are aged 16-70 years with a diagnosis of genital, pharyngeal and/or rectal gonorrhoea. Exclusion criteria are: known concurrent sexually transmitted infection(s) (excluding chlamydia); bacterial vaginosis and/or Trichomonas vaginalis infection; contraindications or an allergy to gentamicin, ceftriaxone, azithromycin or lidocaine; pregnancy or breastfeeding; complicated gonorrhoeal infection; weight under 40 kg; use of ceftriaxone, gentamicin or azithromycin within the preceding 28 days. Randomisation is to receive a single intramuscular injection of either gentamicin or ceftriaxone, all participants receive 1 g oral azithromycin as standard treatment. The estimated sample size is 720 participants (noninferiority limit 5%). The primary outcome is clearance of Neisseria gonorrhoeae at all infected sites by a negative Nucleic Acid Amplification Test, 2 weeks post treatment. Secondary outcomes include clinical resolution of symptoms, frequency of adverse events, tolerability of therapy, relationship between clinical effectiveness and antibiotic minimum inhibitory concentration for N. gonorrhoeae, and cost-effectiveness. DISCUSSION: The options for future treatment of gonorrhoea are limited. Results from this randomised trial will demonstrate whether gentamicin is not clinically worse than ceftriaxone for the treatment of gonorrhoea. This will inform clinical practice and policy for the treatment of gonorrhoea when current therapy with cephalosporins is no longer effective, or is contraindicated. TRIAL REGISTRATION: International Standard Randomised Controlled Trial Number - ISRCTN51783227 , Registered on 18 September 2014. Current protocol version 2.0 17 June 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Brittain C, Childs M, Duley L, et al. Gentamicin versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a randomised trial. Trials. 2016. PMID: 27881151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。